Physician profile
George Tan
NPI 1205071677
$5,393.87
in general payments reported to CMS, 2019-2025
29 companies · $521 in 2025
The $521 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2021: $1,643 · 2022: $1,263 · 2023: $614 · 2024: $483 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.72 |
| Education | $101.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $966.12 | 2021-2025 | Linzess, Viberzi, Skyrizi |
| Cook Medical LLC | $608.20 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $462.78 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Nestle Healthcare Nutrition INC. | $452.57 | 2021-2023 | |
| Janssen Biotech, INC. | $445.06 | 2021-2025 | Stelara, Tremfya, Remicade |
| Braintree Laboratories, INC. | $317.79 | 2021-2023 | Sutab |
| Genzyme Corporation | $281.61 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $275.39 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.33 | 2021-2025 | Eohilia, Entyvio |
| Gilead Sciences, INC. | $179.15 | 2021-2024 | |
| Pfizer INC. | $166.55 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $162.92 | 2021-2024 | Linzess |
| Foundation Medicine, INC. | $148.30 | 2021 | |
| Redhill Biopharma INC. | $123.56 | 2021-2022 | |
| Covidien LP | $118.95 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $77.52 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $58.38 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $52.48 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $42.77 | 2025 | Rezdiffra |
| Ardelyx, INC. | $40.90 | 2022-2023 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $33.29 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $32.62 | 2024 | Omvoh |
| Boston Scientific Corporation | $29.02 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $26.58 | 2024 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $21.03 | 2022 | |
| Lucid Diagnostics INC. | $20.60 | 2023 | |
| Olympus America INC. | $20.52 | 2019 | |
| Celgene Corporation | $19.40 | 2021 | |
| Novo Nordisk INC | $18.48 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.